155 related articles for article (PubMed ID: 23282114)
1. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Shimada YJ
Acta Oncol; 2013 May; 52(4):691-702. PubMed ID: 23282114
[TBL] [Abstract][Full Text] [Related]
2. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Richards CJ; Je Y; Schutz FA; Heng DY; Dallabrida SM; Moslehi JJ; Choueiri TK
J Clin Oncol; 2011 Sep; 29(25):3450-6. PubMed ID: 21810682
[TBL] [Abstract][Full Text] [Related]
4. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D; Lacouture ME; Weiner E; Wu S
Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
[TBL] [Abstract][Full Text] [Related]
5. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
Zhu X; Stergiopoulos K; Wu S
Acta Oncol; 2009; 48(1):9-17. PubMed ID: 18752081
[TBL] [Abstract][Full Text] [Related]
6. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
[TBL] [Abstract][Full Text] [Related]
7. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2014 Dec; 92(3):194-207. PubMed ID: 25028151
[TBL] [Abstract][Full Text] [Related]
8. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1063-73. PubMed ID: 24927771
[TBL] [Abstract][Full Text] [Related]
9. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Je Y; Schutz FA; Choueiri TK
Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
[TBL] [Abstract][Full Text] [Related]
10. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
[TBL] [Abstract][Full Text] [Related]
11. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
Feldt S; Schüssel K; Quinzler R; Franzmann A; Czeche S; Ludwig WD; Schulz M
Eur J Cancer; 2012 May; 48(7):974-81. PubMed ID: 22382202
[TBL] [Abstract][Full Text] [Related]
12. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
13. Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
Porta C; Gore ME; Rini BI; Escudier B; Hariharan S; Charles LP; Yang L; DeAnnuntis L; Motzer RJ
Eur Urol; 2016 Feb; 69(2):345-51. PubMed ID: 26215605
[TBL] [Abstract][Full Text] [Related]
14. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
17. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Jan; 15(1):129-41. PubMed ID: 25482593
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 May; 94(2):238-50. PubMed ID: 25638704
[TBL] [Abstract][Full Text] [Related]
19. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
[TBL] [Abstract][Full Text] [Related]
20. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]